TRACON Pharmaceuticals, Inc. Common Stock
TCON
TCON was delisted on the 27th of June, 2024.
25 hedge funds and large institutions have $24.1M invested in TRACON Pharmaceuticals, Inc. Common Stock in 2016 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 6 increasing their positions, 6 reducing their positions, and 2 closing their positions.
47% more capital invested
Capital invested by funds: $16.4M → $24.1M (+$7.78M)
0% more funds holding
Funds holding: 25 → 25 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
0% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SI
SII Investments
Appleton,
Wisconsin
|
+$202K |
| 2 |
Renaissance Technologies
New York
|
+$81.2K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$13.5K |
| 4 |
Morgan Stanley
New York
|
+$7.89K |
| 5 |
CAM
ClariVest Asset Management
San Diego,
California
|
+$4.51K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$296K |
| 2 |
QF
QVT Financial
New York
|
-$163K |
| 3 |
Stifel Financial
St. Louis,
Missouri
|
-$16.9K |
| 4 |
Wells Fargo
San Francisco,
California
|
-$13.5K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$6.76K |
TCON Hedge Fund Activity: Q3 2016 in Review
25 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in TRACON Pharmaceuticals, Inc. Common Stock (TCON) for Q3 2016, worth a combined $24.1M — up 47% from $16.4M a quarter earlier.
Fund positioning in TCON was balanced in Q3 2016: 2 funds opened new positions, 2 closed out, 6 added to existing stakes and 6 trimmed.
The largest buyer was SII Investments, opening a new position worth an estimated $202K. The largest seller was Deerfield Management, exiting entirely with an estimated $296K sold.
- 25 institutional investors held TRACON Pharmaceuticals, Inc. Common Stock (TCON) as of Q3 2016, unchanged from Q2 2016.
- Funds reported $24.1M of TRACON Pharmaceuticals, Inc. Common Stock stock for Q3 2016, up 47% quarter-over-quarter.
- 2 funds opened new TRACON Pharmaceuticals, Inc. Common Stock positions in Q3 2016 and 2 closed out, a net change of 0 holders.
- The largest TRACON Pharmaceuticals, Inc. Common Stock buyer in Q3 2016 was SII Investments, an estimated $202K added.
- The largest TRACON Pharmaceuticals, Inc. Common Stock seller in Q3 2016 was Deerfield Management, an estimated $296K sold.
Based on aggregated 13F filings for Q3 2016.